effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Post on 12-Feb-2016

37 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

DESCRIPTION

Featured Article :. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity. Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings, M.D. Diabetes Care - PowerPoint PPT Presentation

TRANSCRIPT

Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity

Featured Article:

Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings,

M.D.

Diabetes Care Volume 35: 1420-1428

July, 2012

Study Objectives

 

Cohen R et al. Diabetes Care 2012;35:1420-1428

• Roux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients

• Study determined the long-term impact of RYGB on patients with diabetes and only class I obesity (BMI 30–35 kg/m2 )

Study Design & Methods

• Sixty-six consecutively selected diabetic patients with BMI 30–35 kg/m2 underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1–6]), with 100% follow-up

• Main outcome measures were safety and the percentage of patients experiencing diabetes remission (HbA1c < 6.5% without diabetes medication)

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Cohen R et al. Diabetes Care 2012;35:1420-1428

Conclusions

• Largest, longest-term study to date examining RYGB for diabetic patients without severe obesity

• RYGB safely and effectively ameliorated diabetes and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30–35 kg/m2

Cohen R et al. Diabetes Care 2012;35:1420-1428

top related